Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results?

J Chemother. 2008 Feb;20(1):38-42. doi: 10.1179/joc.2008.20.1.38.

Abstract

The susceptibility profile of 763 Stenotrophomonas maltophilia isolates was evaluated against 16 antimicrobials by the CLSI reference broth microdilution method. Minocycline (MIC(90), 1 microg/ml; 100.0% susceptible) was the most active compound, followed by doxycycline (MIC(90), 4 microg/ml; 99.6% susceptible), trimethoprim/sulfamethoxazole (MIC(90), 1 microg/ml; 97.8% susceptible), and tigecycline (MIC(90), 2 microg/ml). An excellent correlation between levofloxacin (MIC(90), 4 microg/ml; 86.5% susceptible by published breakpoint criteria) and moxifloxacin (MIC(90), 2 micro g/ml) MIC results was observed indicating that moxifloxacin could be further evaluated as a therapeutic option for S. maltophilia infections.

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Aza Compounds / pharmacology*
  • Fluoroquinolones
  • Humans
  • In Vitro Techniques
  • Levofloxacin*
  • Microbial Sensitivity Tests*
  • Moxifloxacin
  • Ofloxacin / pharmacology*
  • Predictive Value of Tests
  • Quinolines / pharmacology*
  • Stenotrophomonas maltophilia / drug effects*
  • Stenotrophomonas maltophilia / isolation & purification

Substances

  • Anti-Bacterial Agents
  • Aza Compounds
  • Fluoroquinolones
  • Quinolines
  • Levofloxacin
  • Ofloxacin
  • Moxifloxacin